Kazia Therapeutics vs Moleculin Biotech
KZIA and MBRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KZIA and MBRX compare
Moleculin Biotech scores higher on the StockData Score (4 against 1 for Kazia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KZIA | MBRX |
|---|---|---|
| Size and price | ||
| Market cap | – | $133M |
| Share price | $5.31 | $6.83 |
| Change, 1 year | −15.3% | −96.9% |
| Change, 5 years | −98.9% | −100.0% |
| Beta (5Y) | 4.08 | −1.10 |
| Employees | 14 | 150K |
| StockData Score | ||
| Total score | 1 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 11.5× |
| Growth | ||
| Revenue growth (TTM) | −98.2% | – |
| Profitability | ||
| Net margin | −49291% | – |
| Return on equity | – | −524% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 2.87 (better) | 0.94 |
| Altman Z-score | – | −11.19 |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.45% | 0.05% |
| Held by insiders | 0.29% | 20.2% |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 0.35% |
Go deeper
- KZIA stock overview
- KZIA income statement
- KZIA valuation and score
- MBRX stock overview
- MBRX income statement
- MBRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.